| Literature DB >> 31331096 |
Sarah Madrières1,2, Guillaume Castel2, Séverine Murri1, Johann Vulin1, Philippe Marianneau1, Nathalie Charbonnel3.
Abstract
Due to their large geographic distribution and potential high mortality rates in human infections, hantaviruses constitute a worldwide threat to public health. As such, they have been the subject of a large array of clinical, virological and eco-evolutionary studies. Many experiments have been conducted in vitro or on animal models to identify the mechanisms leading to pathogenesis in humans and to develop treatments of hantavirus diseases. Experimental research has also been dedicated to the understanding of the relationship between hantaviruses and their reservoirs. However, these studies remain too scarce considering the diversity of hantavirus/reservoir pairs identified, and the wide range of issues that need to be addressed. In this review, we present a synthesis of the experimental studies that have been conducted on hantaviruses and their reservoirs. We aim at summarizing the knowledge gathered from this research, and to emphasize the gaps that need to be filled. Despite the many difficulties encountered to carry hantavirus experiments, we advocate for the need of such studies in the future, at the interface of evolutionary ecology and virology. They are critical to address emerging areas of research, including hantavirus evolution and the epidemiological consequences of individual variation in infection outcomes.Entities:
Keywords: evolutionary ecology; experimentations; hantavirus; immunity; persistence; reservoirs; spill-over; super-spreader; transmission; virology
Year: 2019 PMID: 31331096 PMCID: PMC6669540 DOI: 10.3390/v11070664
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
(a) Laboratory conditions.
| Hantavirus | Reservoir | Experimental Design | Refs | |||||
|---|---|---|---|---|---|---|---|---|
| Species | Viral Strain | Passage History | Species | Sex/Age | Mode of Infection | Virus Dose | Duration | |
| PUUV | ||||||||
| Hällnäs | Passaged twice in laboratory-bred | Suckling (5 to 8 day-old) and weanling (4 to 8 week old) | intramuscular and intracerebral | 103,5 ID50 | 270 days | [ | ||
| Kazan 6 C.g |
| - | intramuscular | 100 ID50 | 13 months | [ | ||
| Kazan-wt | Passaged twice in colonized bank voles | - | subcutaneous | 104 bank vole ID50 | 21 days | [ | ||
|
| ||||||||
| Kazan-wt | - | subcutaneous | 100 bank vole ID50 | 30 days | [ | |||
| Kazan-wt | Colonized | - | subcutaneous | 200 bank vole ID50 | 133 days | [ | ||
| Kazan-wt | Colonized | - | subcutaneous | 100 bank vole ID50 | 38 days | [ | ||
| Sotkamo | Cell culture adapted after numerous passages on Vero E6 strain | Laboratory | Males/Four week old and eight week old | subcutaneous | 3300 ffu | 70 days | [ | |
| Sotkamo | Wild | - | 1—Peat and bedding materials collected from PUUV-infected vole cages | 1–4 weeks | [ | |||
| 2—vole-soiled cages | 2–8 weeks | |||||||
| 3—intranasal (urine) | 3–8 weeks | |||||||
| Sotkamo | Wild | - | subcutaneous | 1.7 × 103 ffu | 35 days | [ | ||
| Sotkamo | Wild | - | subcutaneous | 1.7 × 103 ffu | 55 days | [ | ||
| K27 | Vero-E6 cells | Laboratory | Females/6–8 weeks | intragastrically | 1 | 35 days | [ | |
| pfu; 10,000 pfu or 10,000 pfu γ-irradiated | ||||||||
| PUUV (3 × 10 6 rad) | ||||||||
| SEOV | ||||||||
| SR-11 | Four times in Vero E6 cells | Long Evans rats | Males and females/70–80 days | - | 10-4, 10-3, 10−2, 102, 104 or 106 pfu | 40 days | [ | |
| SR-11 | SPF Wistar rats ( | - | intraperitoneal | - | [ | |||
| SR-11 | Long Evans rats ( | Males and females/>70 days | intraperitoneal | 104 pfu | 40 days | [ | ||
| SR-11 | Long Evans rats ( | Males and females/70–80 days | intraperitoneal | 104 pfu | 40 days | [ | ||
| SR-11 | Long Evans rats ( | Males/60–70 days | intraperitoneal | 104 pfu | 60 days | [ | ||
| SR-11 | Long Evans rats ( | Males/60–70 days | intraperitoneal | 104 pfu | 40 days | [ | ||
| SR-11 | Long Evans rats ( | Males and females/60–70 days | intraperitoneal | 104 pfu | 40 days | [ | ||
| Type B-1 | Vero E6 cells | Laboratory rats ( | Females/neonates | intraperitoneal | 5 × 103 or 5 × 105 LD50 | - | [ | |
| Type B-1 | Laboratory rats ( | Female/neonates | intraperitoneal | 5 × 103 or 5 × 105 LD50 | - | [ | ||
| Type B-1 | Laboratory rats ( | Females/neonates | intraperitoneal | 5 × 103 or 5 × 105 LD50 | - | [ | ||
| Type B-1 | - | Laboratory F344/Jcl rats ( | 2 to 3 months old | intraperitoneal | - | - | [ | |
| KI-83-262 | Seven days on Vero E6 cells | Wistar rats ( | Newborn (<24 h) and 8 weeks old | intraperitoneal | 6.6 × 103 ffu | - | [ | |
| KI-83-262 | Wistar rats ( | Newborn (<24 h) and 7 weeks old | intraperitoneal | 6.6 × 103 ffu | - | [ | ||
| 80–39 | Three times in Wistar rats and six times in Vero E6 cells | Inbred Lewis rats ( | 6, 10 or 21 days | intraperitoneal | 106 TCID50 of virus stock in 0.1 ml | 84 days | [ | |
| HTNV | ||||||||
| 76–118 | Eight passages in weanling rats and two in suckling rats | Wild | Adults | intramuscular | 105.9 ID50/0,3 mL or 108,2 ID50/0,3 mL | - | [ | |
| 76–118 | Large array of species, including colonized and wild rodents | - | intramuscular or intralung | 103,5–105,2 infectious units/mL | - | [ | ||
| 76118 | Fischer F 344/N rats ( | Suckling (1 to 3 day old) and weanling (4 week old) | intramuscular and intracerebral | 106 and 108,5 ID50 | 180 or 360 days | [ | ||
| SNV | ||||||||
| SN77734 | 4 to 6 week-old | intramuscular | 5 doses of ID50 | 217 days | [ | |||
| SN77734 | In vivo within deer mice | - | intramuscular | 5 doses of ID50 | 120 days | [ | ||
| SN77734 | Outbred | Males and females/6 to 10 weeks | intramuscular | 20 animal ID50 | 20 days | [ | ||
| SN77734 | Colonized | - | intramuscular | the equivalent of 2 × 105 genome copies | 6 weeks | [ | ||
| SN77734 |
| Males and females/6 to 10 weeks | intramuscular | 20 animal ID50 | 45 days | [ | ||
| SN77734 | Wild | - | - | - | - | [ | ||
| BCCV | ||||||||
| - | Three times in Vero E6 cells | Laboratory cotton rats ( | Males/four week-old | subcutaneous | 1000 TCID50 | 150 days | [ | |
| - | Three times in Vero E6 cells | Laboratory cotton rats ( | 3 weeks to 4 months | subcutaneous | 1000 TCID50 | - | [ | |
| ANDV | ||||||||
| ANDV-9717869 | Vero E6 cells | Laboratory | Females/6 to 8 weeks old | intramuscular, intragastric, subcutaneous, intranasal | 35 days | [ | ||
| ANDV-9717869 | Outbred | Males/6 to 12 weeks old | intramuscular | 200 ffu | 56 days | [ | ||
| CDGV | ||||||||
| VHV-574 | Vero E6 cells | Laboratory | 21 days | subcutaneous | 3.1, 1.1, −0.9, or −2.9 log10 CCID50 | 54 days | [ | |
| TULV | ||||||||
| Moravia/Ma5302V/9 | - | - | subcutaneous | 2 × 103 ffu | 21 days | [ | ||
| DOBV | ||||||||
| Slovenia | - |
| subcutaneous | 5 × 103 ffu | 21 days | [ | ||
| MAPV | ||||||||
| HV 9702105 | Vero E6 cells |
| Males and females/8–16 weeks | subcutaneous | 104 TCID50 | 56 and 14 days | [ | |
| RIOMV | ||||||||
| HTN-0007 | Vero E6 cells | Wild | - | intraperitoneal | 103 RNA copies | 18 days | [ | |
ID50: Median Infectious Dose; TCID50: Tissue culture Infective Dose; CCID50: median cell culture infectious dose; ffu: focus forming units; pfu: plaque-forming units.
(b) Environmental conditions.
| Hantavirus/Reservoir | Experimental Design | Duration | Refs |
|---|---|---|---|
| PUUV/ | |||
| Capture-Mark-Recapture (CMR) | 5 years | [ | |
| CMR | 7 years | [ | |
| CMR | Three consecutive winters | [ | |
| CMR | 3 years | [ | |
| CMR | 16 months | [ | |
| SNV/ | |||
| CMR | 2 years | [ | |
| CMR | 2 years | [ | |
| CMR | 15 years | [ | |
| CMR | 6 years | [ | |
| CMR | Spring and fall | [ | |
| CMR | 7 months to 4 years | [ | |
| CMR | 5 years | [ | |
| CMR | Spring and fall | [ | |
| CMR | 2 years | [ | |
| Outdoor enclosure | 1 year | [ | |
| Outdoor enclosures | 8 months | [ | |
| SNV/Rodent community | |||
| Outdoor enclosures | 2 months | [ | |
| ANDV/Sigmodontine rodents | |||
| Outdoor enclosure | 2 years | [ | |
| SEOV/ | |||
| CMR | 2 years | [ | |
| CMR | 3 years | [ | |
| MRPV/ | CMR | 5 months | [ |